Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

413
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
413

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Nature communications·2026
Same author

Is there an association between acute, subacute, and late genitourinary quality of life with prostate SBRT boost?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.

The Lancet. Oncology·2026
Same author

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.

The Lancet. Oncology·2026
Same author

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.

European urology·2026
Same author

Interlocking host and viral cis-regulatory networks drive Merkel cell carcinoma.

The Journal of clinical investigation·2025

Related Experiment Video

Updated: Aug 19, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

340

Modern Active Surveillance in Prostate Cancer: A Narrative Review.

Trent A Pattenden1, Dhanika Samaranayke2, Andrew Morton2

  • 1Department of Urology, Ipswich Hospital, QLD, Australia.

Clinical Genitourinary Cancer
|November 28, 2022
PubMed
Summary

Active surveillance for prostate cancer helps avoid overtreatment of indolent disease. This review covers its safety, current criteria, incidence, barriers, and future patient selection methods for active surveillance.

Keywords:
Active surveillanceIntermediate risk prostate cancerLow risk prostate cancerMRIRisk stratification

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.6K
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:08

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

146

Related Experiment Videos

Last Updated: Aug 19, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

340
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.6K
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:08

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

146

Area of Science:

  • Urologic Oncology
  • Oncology
  • Public Health

Background:

  • Prostate-specific antigen (PSA) screening increases detection of indolent prostate cancer.
  • Over-treatment of low-risk prostate cancer leads to significant morbidity.
  • Active surveillance (AS) is a strategy to mitigate overtreatment.

Purpose of the Study:

  • To review evidence supporting the safety of active surveillance for prostate cancer.
  • To outline current and recommended selection criteria and monitoring schedules for AS.
  • To discuss the incidence, barriers, and future developments in AS patient selection.

Main Methods:

  • Literature review of studies on active surveillance for prostate cancer.
  • Analysis of evidence regarding AS safety, efficacy, and patient selection.
  • Examination of factors influencing AS uptake and future research directions.

Main Results:

  • Evidence supports the safety of AS in carefully selected prostate cancer patients.
  • Lack of consensus exists regarding optimal AS selection criteria and monitoring.
  • Barriers to AS uptake include physician and patient factors, and system-level issues.

Conclusions:

  • Active surveillance is a viable strategy for managing low-risk prostate cancer.
  • Standardized criteria and improved monitoring are needed to optimize AS.
  • Future developments in genomics and imaging may enhance patient selection for AS.